Company intelligence / Profile preview
Kumquat Biosciences
- Ownership
- Private
- Development stage
- Preclinical
Overview
Kumquat Biosciences has multiple small molecule oncology programs in early clinical development, with a focus on targeting the KRAS/RAS pathways using proprietary covalent chemistry. The company’s most advanced assets are in Phase 1 trials. It recently entered a major partnership with Takeda to develop an oral small molecule inhibitor, with Kumquat leading Phase 1 before Takeda takes over further development. No published late-stage clinical results yet.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesImmuno-oncology therapiesCovalent inhibitors (platform technology)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Kumquat Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kumquat Biosciences.